Joel C. Wight

Townsville, QLD, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Journal: Internal medicine journal
Published: January 06, 2026

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study.

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study.

Journal: HemaSphere
Published: December 17, 2025

Effective management of daratumumab-induced cytopenias with hematopoietic stem cell infusion in relapsed/refractory multiple myeloma: a case report.

Effective management of daratumumab-induced cytopenias with hematopoietic stem cell infusion in relapsed/refractory multiple myeloma: a case report.

Journal: Leukemia & lymphoma
Published: November 24, 2025

Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.

Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.

Journal: Leukemia & lymphoma
Published: July 27, 2025

T-Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B-Cell Lymphoma.

T-Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B-Cell Lymphoma.

Journal: EJHaem
Published: January 06, 2025

Low flow: Selecting a limited flow cytometry panel where resources are constrained.

Low flow: Selecting a limited flow cytometry panel where resources are constrained.

Journal: Blood reviews
Published: December 19, 2024

Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.

Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.

Journal: EJHaem
Published: May 09, 2024

Erratum to: Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes.

Erratum to: Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes.

Journal: Haematologica
Published: April 01, 2024

Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study.

Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study.

Journal: British journal of haematology
Published: December 20, 2023

Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillance.

Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillance.

Journal: Haematologica
Published: November 01, 2023

Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.

Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.

Journal: Internal medicine journal
Published: April 18, 2023

Coagulopathy is an under-recognised complication of acquired HLH.

Coagulopathy is an under-recognised complication of acquired HLH.

Journal: BMJ case reports
Published: January 11, 2023
Showing 1-12 of 33

Last Updated: 09/26/2026